Michael Bailey is a veteran biopharmaceutical executive who has served as president and CEO of AVEO Oncology since 2015, leading the company through a strategic transformation from a research-focused organization to a commercial-stage oncology company.
Under Bailey’s leadership AVEO secured FDA approval of tivozanib (FOTIVDA) in 2021 for adult patients with relapsed or refractory advanced renal cell carcinoma (RCC), a milestone that enabled the company to bring a new oral therapy to market. Bailey is credited with revitalizing the company’s pipeline and navigating complex regulatory challenges, including responding to a 2020 FDA rejection by initiating a second Phase 3 study that ultimately supported approval.
In early 2023 AVEO was acquired by LG Chem for $566 million, establishing AVEO as the commercial foundation for LG Chem’s U.S. oncology operations and expanding resources for its diversified pipeline. Under Bailey’s continued direction the company is advancing candidates such as ficlatuzumab for head and neck cancer and exploring new combinations for tivozanib, with recent data presented at ASCO GU 2025. AVEO also earned “Top Places to Work” recognition in 2023, reflecting efforts to build a mission-driven organizational culture.
The 100 CEOs featured in this series reflect the diversity and complexity of contemporary oncology leadership. In 2025 they include leaders of major cancer institutions, heads of specialized societies and executives at emerging innovators, all responsible for millions of patients, the integrity of scientific research and the future direction of cancer care.
This list recognizes stewardship, accountability and impact rather than power. The publication will continue to acknowledge and elevate other deserving leaders in daily coverage from around the world.
Leave a Reply